Thrombolysis in acute ischaemic stroke: time for a rethink?

2015/03/17 by Brian S. Alper, Meghan Malone-Moses, Jason S. McLellan +2 · 1 citation
Medicine · Engineering · #Acute Ischemic Stroke Management #Cerebrovascular and Carotid Artery Diseases #Traumatic Brain Injury and Neurovascular Disturbances #Thrombolysis #Ischaemic stroke #Cardiology #Medicine #Stroke (engine) #Internal medicine #Acute stroke #Tissue plasminogen activator #Ischemia #Myocardial infarction #Engineering

paper · doi:10.1136/bmj.h1075

openalex publication_date 2015/03/17 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/05

Abstract

As the UK regulator reviews alteplase in ischaemic stroke, <b>Brian Alper and colleagues</b> interpret the evidence to suggest increased mortality with uncertain benefit for its use beyond three hours

Cited by

• Stroke [wikipedia]

Related

• Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials
• Extending thrombolysis to 4·5–9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data
• Thrombolysis for acute ischaemic stroke
• Treatments in Ischemic Stroke: Current and Future
• Acute ischaemic stroke: recent advances in reperfusion treatment